Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
79.49
+4.39 (5.85%)
At close: Jan 22, 2026, 4:00 PM EST
78.61
-0.88 (-1.11%)
After-hours: Jan 22, 2026, 4:54 PM EST
Inhibrx Biosciences Revenue
In the year 2024, Inhibrx Biosciences had annual revenue of $200.00K, down -88.89%.
Revenue (ttm)
$200.00K
Revenue Growth
-88.89%
P/S Ratio
825.77
Revenue / Employee
$8,696
Employees
161
Market Cap
1.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 200.00K | -1.60M | -88.89% |
| Dec 31, 2023 | 1.80M | -392.00K | -17.88% |
| Dec 31, 2022 | 2.19M | -5.04M | -69.69% |
| Dec 31, 2021 | 7.23M | -5.66M | -43.89% |
| Dec 31, 2020 | 12.89M | -323.00K | -2.44% |
| Dec 31, 2019 | 13.21M | 4.62M | 53.71% |
| Dec 31, 2018 | 8.60M | 204.00K | 2.43% |
| Dec 31, 2017 | 8.39M | 1.72M | 25.86% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 147.19M |
| ARS Pharmaceuticals | 142.77M |
| Theravance Biopharma | 80.33M |
| Inventiva | 19.93M |
| Zenas BioPharma | 15.00M |
| Nanobiotix | 11.93M |
| Aktis Oncology | 5.56M |
| Compass Therapeutics | 850.00K |
INBX News
- 12 hours ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 9 days ago - Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too - Seeking Alpha
- 4 weeks ago - Why Inhibrx's Recent Strength May Not Be Built to Last - Benzinga
- 5 weeks ago - Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program - PRNewsWire
- 2 months ago - Inhibrx Reports Third Quarter 2025 Financial Results - PRNewsWire
- 2 months ago - Inhibrx Announces Participation in Upcoming Scientific Conferences - PRNewsWire
- 3 months ago - Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing - Seeking Alpha
- 3 months ago - Inhibrx shares surge after bone cancer drug slows disease progression in trial - Reuters